FDA Scrutiny on Sarepta

News

Gene Therapy Stays on Market Despite FDA Request

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment died,

InvestorsHub on MSN · 8h

Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy

Fierce Pharma · 8h

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

pharmaphorum13h

Sarepta resists as FDA seeks pause on Elevidys use

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

4hon MSN

Sarepta shares cut to $0 at H.C. Wainwright

H.C. Wainwright sets a rare $0 target for Sarepta Therapeutics amid FDA scrutiny over its Duchenne muscular dystrophy gene therapy Elevidys. Read more here.

Hoodline1d

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

2don MSN

Sarepta Therapeutics laying off nearly 500 employees, including 80 in Franklin County

Sarepta Therapeutics announced a layoff of 493 employees, including 80 in Franklin County, amid restructuring efforts and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results